{"id":745097,"date":"2015-10-05T18:01:00","date_gmt":"2015-10-05T18:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/"},"modified":"2025-11-07T01:24:54","modified_gmt":"2025-11-07T06:24:54","slug":"results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/","title":{"rendered":"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the publication of results from <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02092350&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=C-SURFER&amp;index=1&amp;md5=a9082e48979d177cfdcfa77588aae200\" rel=\"nofollow\"><i>C-SURFER<\/i><\/a>,<br \/>\n      the first Phase 3<sup>1<\/sup> clinical trial to investigate an all-oral,<br \/>\n      ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in<br \/>\n      treatment-na\u00efve and treatment-experienced patients with advanced chronic<br \/>\n      kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1)<br \/>\n      infection. Data from the Phase 3 clinical trial evaluating the<br \/>\n      investigational, once-daily treatment regimen of elbasvir (50mg)<sup>2<\/sup><br \/>\n      and grazoprevir (100mg)<sup>3<\/sup> in patients with advanced CKD were<br \/>\n      published online in the medical journal <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2815%2900349-9%2Fabstract&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=The+Lancet&amp;index=2&amp;md5=30b32263976e7ad7ea148acc5246771b\" rel=\"nofollow\"><i>The<br \/>\n      Lancet<\/i><\/a>. Data from this study were initially presented at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Filc-congress.eu%2F&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=The+International+Liver+CongressTM+2015&amp;index=3&amp;md5=8607e2bfcbb685da5e658163912e7c26\" rel=\"nofollow\">The<br \/>\n      International Liver Congress<sup>TM <\/sup>2015<\/a><span class=\"bwuline\"> <\/span>in<br \/>\n      April 2015; additional information about that presentation and the<br \/>\n      design of the study can be found on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmerck-announces-results-phase-23-study-investigational-chronic-hep&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=the+Merck+newsroom&amp;index=4&amp;md5=d3e046c884b36a27a73193a5a2bb9971\" rel=\"nofollow\">the<br \/>\n      Merck newsroom<\/a>.\n    <\/p>\n<p>\n      \u201cPeople with advanced chronic kidney disease represent an important<br \/>\n      segment of the chronic hepatitis C patient population,\u201d said Dr. Howard<br \/>\n      Monsour, Jr., chief of hepatology, Houston Methodist Hospital. \u201cThe<br \/>\n      publication of this study details the evidence supporting a potential<br \/>\n      future treatment option for these patients who are currently<br \/>\n      underserved.\u201d\n    <\/p>\n<p>\n      The peer-reviewed, published results show that 12 weeks of therapy with<br \/>\n      elbasvir plus grazoprevir in patients with chronic HCV GT1 infection and<br \/>\n      advanced CKD resulted in high rates of sustained virologic response 12<br \/>\n      weeks after the completion of treatment (SVR12). High rates of SVR were<br \/>\n      achieved regardless of patient characteristics in this study, including<br \/>\n      African-American patients, patients receiving hemodialysis and patients<br \/>\n      with the <i>IL28B<\/i> non-CC genotype. Among those receiving elbasvir<br \/>\n      plus grazoprevir in the primary analysis population, 99 percent<br \/>\n      (115\/116) achieved SVR12, with one relapse 12 weeks after the end of<br \/>\n      treatment. In a secondary analysis that included six additional patients<br \/>\n      excluded from the primary efficacy analysis for non-virologic reasons<br \/>\n      (study discontinuation unrelated to study drug, loss to follow-up,<br \/>\n      noncompliance, etc.), 94 percent (115\/122) achieved SVR12. Adverse<br \/>\n      events reported at or above 10 percent frequency in the active and<br \/>\n      placebo treatment groups included headache, nausea and fatigue; rates in<br \/>\n      the active treatment group were comparable to those in the group that<br \/>\n      received placebo for the first 12 weeks.\n    <\/p>\n<p>\n      <b>About Chronic HCV Infection and Chronic Kidney Disease<\/b>\n    <\/p>\n<p>\n      Chronic HCV infection is both a cause and complication of the treatment<br \/>\n      of CKD. In patients with CKD, chronic HCV infection is associated with<br \/>\n      an increased risk of accelerated loss of remaining kidney function,<br \/>\n      kidney transplant failure and death. Furthermore, patients with chronic<br \/>\n      HCV infection and advanced CKD represent an unmet need due to a lack of<br \/>\n      demonstrated HCV treatment options for this group.\n    <\/p>\n<p>\n      <b>About Elbasvir\/Grazoprevir<\/b>\n    <\/p>\n<p>\n      Elbasvir\/grazoprevir is Merck\u2019s investigational, once-daily, fixed-dose<br \/>\n      combination therapy containing elbasvir (HCV NS5A replication complex<br \/>\n      inhibitor) and grazoprevir (HCV NS3\/4A protease inhibitor). Evaluations<br \/>\n      of elbasvir\/grazoprevir for multiple HCV genotypes as part of Merck\u2019s<br \/>\n      broad clinical trials program include patients with difficult-to-treat<br \/>\n      conditions such as cirrhosis, advanced chronic kidney disease, HIV\/HCV<br \/>\n      co-infection, inherited blood disorders and those on opiate substitution<br \/>\n      therapy. In July 2015, the U.S. Food and Drug Administration (FDA)<br \/>\n      granted Priority Review for the New Drug Application for<br \/>\n      elbasvir\/grazoprevir, with a Prescription Drug User Fee Act (PDUFA)<br \/>\n      action date of Jan. 28, 2016.\n    <\/p>\n<p>\n      In April 2015, the FDA granted Breakthrough Therapy designation status<br \/>\n      for elbasvir\/grazoprevir for the treatment of patients with chronic HCV<br \/>\n      GT1 infection with end stage renal disease on hemodialysis, and<br \/>\n      Breakthrough Therapy designation status for elbasvir\/grazoprevir for the<br \/>\n      treatment of patients with chronic HCV GT4 infection. Breakthrough<br \/>\n      Therapy designation is intended to expedite the development and review<br \/>\n      of a candidate that is planned for use, alone or in combination, to<br \/>\n      treat a serious or life-threatening disease or condition when<br \/>\n      preliminary clinical evidence indicates that the drug may demonstrate<br \/>\n      substantial improvement over existing therapies on one or more<br \/>\n      clinically significant endpoints.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to deliver innovative<br \/>\n      health care solutions that support people living with HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=df139c3ff469e79b67dacfec39eac01d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=97d88c194cfc9b956ccbe21c7cf61171\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=2b142751327278e73501acd212521ee3\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=44ca3b8755e618e2568c28be28d56215\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51194873&amp;newsitemid=20151005006479&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=209445763c1d2bdf1d3d3d6ac5a28146\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Included small Phase 2 pharmacokinetic assessment\u00a0<br \/><sup>2<\/sup><br \/>\n      Elbasvir is an HCV NS5A replication complex inhibitor\u00a0<br \/><sup>3<\/sup><br \/>\n      Grazoprevir is an HCV NS3\/4A protease inhibitor\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151005006479r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Doris Li, 908-246-5701<br \/>Sarra        Herzog, 201-669-6570<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam,        908-740-1986<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER , the first Phase 3 1 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-na\u00efve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg) 2 and grazoprevir (100mg) 3 in patients with advanced CKD were published online in the medical journal The Lancet . Data from this study were initially presented at The International Liver CongressTM 2015 in April 2015; additional information about that presentation and the design of the study can be found on the Merck newsroom . \u201cPeople with advanced chronic kidney disease represent an important segment of the chronic hepatitis C patient population,\u201d said Dr. Howard<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745097","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER , the first Phase 3 1 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-na\u00efve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg) 2 and grazoprevir (100mg) 3 in patients with advanced CKD were published online in the medical journal The Lancet . Data from this study were initially presented at The International Liver CongressTM 2015 in April 2015; additional information about that presentation and the design of the study can be found on the Merck newsroom . \u201cPeople with advanced chronic kidney disease represent an important segment of the chronic hepatitis C patient population,\u201d said Dr. Howard\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\\\/\",\"name\":\"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\\\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-10-05T18:01:00+00:00\",\"dateModified\":\"2025-11-07T06:24:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\\\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/","og_locale":"en_US","og_type":"article","og_title":"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER , the first Phase 3 1 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-na\u00efve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Data from the Phase 3 clinical trial evaluating the investigational, once-daily treatment regimen of elbasvir (50mg) 2 and grazoprevir (100mg) 3 in patients with advanced CKD were published online in the medical journal The Lancet . Data from this study were initially presented at The International Liver CongressTM 2015 in April 2015; additional information about that presentation and the design of the study can be found on the Merck newsroom . \u201cPeople with advanced chronic kidney disease represent an important segment of the chronic hepatitis C patient population,\u201d said Dr. Howard","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/","name":"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-10-05T18:01:00+00:00","dateModified":"2025-11-07T06:24:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/results-from-mercks-phase-3-study-of-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir-in-patients-with-advanced-chronic-kidney-disease-published-in-the-lancet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Results from Merck\u2019s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0eb5e142-6446-48fb-941d-bc4940a58001","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745097\/revisions"}],"predecessor-version":[{"id":3674588,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745097\/revisions\/3674588"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745097"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}